The N-acetyltransferase arrest defective 1 (ARD1) is an important regulator of cell growth and differentiation that has emerged recently as a critical molecule in cancer progression. However, the regulation of the enzymatic and biological activities of human ARD1 (hARD1) in cancer is presently poorly understood. Here, we report that hARD1 undergoes autoacetylation and that this modification is essential for its functional activation. Using liquid chromatography-tandem mass spectrometry and site-directed mutational analyses, we identified K136 residue as an autoacetylation target site. K136R mutation abolished the ability of hARD1 to promote cancer cell growth in vitro and tumor xenograft growth in vivo. Mechanistic investigations revealed that hARD1 autoacetylation stimulated cyclin D1 expression through activation of the transcription factors β-catenin and activator protein-1. Our results show that hARD1 autoacetylation is critical for its activation and its ability to stimulate cancer cell proliferation and tumorigenesis. Cancer Res; 70(11); 4422-32. ©2010 AACR.
Introduction
Posttranslational modification is a pivotal regulatory molecular switch of cell signaling pathways and gene expression. Most well-established examples are kinase cascades in which phosphorylation/dephosphorylation events can function as the basis for signal transduction. A number of kinases can be activated by an autoregulatory system called autophosphorylation (1, 2) . Discovery of the autoacetylation could extend this autoregulatory system to acetyltransferases (3) . Like autophosphorylation, acetyltransferases acetylate themselves for its catalytic and functional activities (4) (5) (6) (7) (8) (9) .
Arrest defective 1 (ARD1) was originally identified to catalyze NH 2 -terminal α-acetylation in yeast (10) . Subsequently, several studies revealed that mammalian ARD1 catalyzes also ε-lysine acetylation of hypoxia-inducible factor-1α, β-catenin, myosin light chain kinase, and tubulin fractions (11) (12) (13) (14) (15) (16) (17) . ARD1 is closely related to cellular growth. In human cells, knockdown of human ARD1 (hARD1) inhibits cellular growth and induces G 1 arrest (12, 13, 18) . Recently, a number of links have been found between increased expression of hARD1 and human cancers, including breast, prostate, lung, and colorectal cancers (19) (20) (21) (22) . Therefore, ARD1 is increasingly recognized as an important molecule involved in cancer progression, but nevertheless, the regulation of its biological activity remains largely unknown.
Here, we found that autoacetylation serves as a key regulatory switch of hARD1. This modification plays a crucial role in cell cycle regulation through the increase in cyclin D1 expression mediated by β-catenin and activator protein-1 (AP-1). These findings provide new insights into the understanding how hARD1 exerts its biological and molecular behavior in cancer cell proliferation and cancer progression.
Materials and Methods

siRNA and plasmids
hARD1 siRNA sequence corresponds to CCUCUCGAGC-CAUGAUAGA (Dharmacon). For hARD1 reconstitution experiments, cells were transfected with 5′-untranslated region (UTR) hARD1 siRNA targeting the 5′-UTR, of which sequence corresponds to CUGACUGCGCUUCACGAU (Dharmacon). hARD1 expression vectors were constructed by PCR and subcloned into pCDAN3.1 and pCS2 + GFP for cell expressing vector or pET-28 and pGEX-4T for bacterial induction of the recombinant protein.
Cell culture and transfection A549, HEK293T, HeLa, and H460 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 humidified atmosphere at 37°C and transfected with Lipofectamine or Oligofectamine (Invitrogen). When required, cells were serum starved for 24 hours and either analyzed immediately or stimulated with 100 nmol/L 12-Otetradecanoylphorbol-13-acetate (TPA).
Immunoblotting and immunoprecipitations
Cells were extracted in NP40 buffer [10 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40 buffer]. Lysates were immunoblotted or immunoprecipitated with corresponding primary antibody. A polyclonal antibody to hARD1 was produced by Dinona. Antibodies for cyclin D1, c-Jun, c-Fos, green fluorescent protein (GFP), and myc were purchased from Santa Cruz Biotechnology, and acetyl-lysine antibody was from Cell Signaling.
In vitro acetylation assay
Freshly prepared recombinant hARD1 was incubated in the reaction mixture [50 mmol/L Tris-HCl (pH 8.0), 0.1 mmol/L EDTA, 1 mmol/L DTT, 10% glycerol, and 10 mmol/L acetyl-CoA or 14 C-labeled acetyl-CoA] at 30°C. When required, after incubation, His-hARD1 was cleaved by overnight incubation with thrombin at 4°C.
Cell viability assay
The proliferation rates were measured using a NonRadioactive Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. Briefly, 20 μL of freshly mixed tetrazolium/phenazine methosulfate were added, and the cells were incubated for 1 hour to allow color development. The absorbance at 490 nm was measured to indicate the number of proliferating cells.
Soft agar colony formation assay
Transfected cells were trypsinized, counted, and resuspended in 2 mL DMEM supplemented with 10% FBS and 0.35% agar. The cell mixture was seeded on a layer of 0.7% bottom agar in six-well plates and allowed to grow. After 3 weeks of incubation, colonies were examined with 0.005% crystal violet stain and counted.
Thymidine incorporation assay
Cells were treated with [methyl-3 H]thymidine at a final concentration of 1 mCi/mL. After 24 hours of incubation, cells were harvested and ice-cold 10% trichloroacetic acid solution (20 mL) was added to the cell pellet. The pellet was mixed with 400 mL of 0.2 N NaOH and 0.5% SDS and then incubated at 37°C for 30 minutes. After incubation, samples were mixed with 1 N HCl. Radioactivity was measured by liquid scintillation counting.
RNA analysis and semiquantitative reverse transcription-PCR
Total RNA was extracted using an RNA extraction kit (Invitrogen). Complementary DNA was synthesized from 5 μg of total RNA using an oligo(dT) primer. Primers used for PCR were as follows: human cyclin D1, 5′-CTGGCCATGAAC-TACCTGGA-3′ (forward) and 5′-GTCACACTTGATCACTC-TGG-3′ (reverse); hARD1, 5′-ATGAACATCCGCAATGCGAG-3′ (forward) and 5′-CTAGGAGGCTGAGTCGGAGG-3′ (reverse); c-Jun, 5′-GAAACGACCTTCTATGACGAT-3′ (forward) and 5′-CTGCTCATCTGTCACGTTCTT-3′ (reverse); c-Fos, 5′-CTAC-G A G G C G T C A T C C T C C -3 ′ ( f o r w a r d ) a n d 5 ′ -C C T -CCGGTTGCGGCATTTG-3′ (reverse). The PCR amplification was carried out for 25 cycles for cyclin D1 and hARD1, 30 cycles for c-Jun, and 27 cycles for c-Fos.
Electrophoretic mobility shift assay
Nuclear extracts were incubated with 32 P-labeled AP-1 binding oligonucleotide (Promega) for 1 hour in 15 μL of buffer containing 10 mmol/L Tris (pH 7.5), 200 mmol/L NaCl, 1 mmol/L DTT, 1 mmol/L EDTA, 5% glycerol, and 0.5 μg sperm DNA. DNA-protein complexes were separated by electrophoresis, and gels were dried and visualized by autoradiography. Supershift experiments were performed by addition of c-Jun or c-Fos antibody to the nuclear extract 15 minutes before the formation of DNA-protein complexes.
Luciferase assay 5xTRE-Luc reporter construct was kindly provided by Dr. K. Sabapathy (National University of Singapore, Singapore, Singapore; ref. 23) , cyclin D1 promoter (−961 to +134)-Luc and AP-1 site-deleted cyclin D1 promoter-Luc reporter construct were kindly provided by Dr. R.G. Pestell (Thomas Jefferson University, Philadelphia, PA; ref. 24) , and TOP-Luc reporter was kindly provided by Dr. K.Y. Choi (Yonsei University, Seoul, Korea; ref. 25) . Luciferase activities were analyzed using Luciferase assay kit (Promega) according to the manufacturer's instructions. Transfection efficiencies were normalized by β-galactosidase (β-Gal) assays.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were carried out as described previously (26) . Briefly, cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature and formaldehyde was then inactivated by the addition of 125 mmol/L glycine. Chromatin extracts containing DNA fragments were immunoprecipitated using 5 mg of anti-c-Jun or anti-cFos or β-catenin antibody. Following DNA purification, the presence of selected DNA sequences was assessed by PCR. Cyclin D1 gene promoter-specific primers used were as follows: AP-1 site, 5′-CTGCCTTCCTACCTTGACCA-3′ (forward) and 5′-TGAAGGGACGTCTACACCCC-3′ (reverse); T-cell factor 4 (TCF4) site, 5′-AGGCGCGGCGGCTCAGGGATG-3′ (forward) and 5′-TTGCAACTTCAACAAAACTC-3′ (reverse).
Statistical analysis
P values were calculated by applying the two-tailed Student's t test to data from three independent experiments.
Results
hARD1 is acetylated by itself
Recombinant hARD1 was acetylated by incubation with acetyl-CoA in a time-dependent manner, whereas autoacetylation disappeared on denaturation of hARD1 by 0.1% SDS or when acetyl-CoA was absent (Fig. 1A, left) . Autoacetylation activity of hARD1 was also determined by autoradiography after the incubation with [
14 C]acetyl-CoA, resulting in strong acetylation of hARD1 (Fig. 1A, right) .
Based on previous reports (14, 27, 28) and structural alignment with other acetyltransferase (data not shown), we predicted two putative active sites, Arg 82 (R82) and Tyr 122 (Y122; Fig. 1B ), and determined whether these sites are important for the catalytic activity of hARD1. Whereas wild-type (WT) hARD1 underwent autoacetylation, the R82A and Y122F mutations markedly abolished the autoacetylation activity of hARD1 (Fig. 1C) , indicating that acetylation of hARD1 requires its own catalytic activity, excluding the possibility that other nonspecific components mixed with recombinant Figure 1 . hARD1 acetylates itself in vitro. A, in vitro autoacetylation of hARD1. Purified recombinant GST-hARD1, His-hARD1, and GST (as a control protein) were subjected to the in vitro acetylation assay for the indicated times. Acetylated proteins were detected by anti-acetyl-lysine (Lys-Ac) antibody (left) or incorporation of [ 14 C]acetyl-CoA (right). Coomassie brilliant blue staining shows the quantification of the input proteins. B, prediction of active sites of hARD1. The sequence of hARD1 was compared with human serotonin N-acetyltransferase (hSNAT) and human spermidine/spermine N-acetyltransferase (hSSAT). The two predicted active sites, R82 and Y122, are highlighted. C, catalytic active site of hARD1. His-tagged WT hARD1 or putative active site-mutated hARD1 recombinants were subjected to the in vitro acetylation assay. Top, autoacetylation status was analyzed using anti-acetyl-lysine antibody; bottom, Coomassie brilliant blue staining shows the quantification of the input proteins. D, autoacetylation of hARD1 does not occur via an intermolecular event. GST-hARD1 and His-R82A/Y122F mutant hARD1 recombinants were incubated together with acetyl-CoA. Top, acetylated hARD1 was identified with the anti-acetyl-lysine antibody; bottom, total proteins were stained with Coomassie brilliant blue. hARD1 acetylated hARD1. To examine whether autoacetylation of hARD1 occurs via an intermolecular event, His-R82A/ Y122F mutant (which cannot autoacetylate) was used as a substrate for glutathione S-transferase (GST)-WT hARD1. Incubation of GST-WT hARD1 together with His-R82A/ Y122F mutant resulted in acetylation of GST-WT hARD1 only, indicating that WT hARD1 cannot acetylate R82A/ Y122F mutant intermolecularly (Fig. 1D) .
Autoacetylation occurs at K136 residue of hARD1
To identify the specific site of autoacetylation, two recombinant hARD1 samples, control (without acetyl-CoA) and autoacetylated (with acetyl-CoA) hARD1 recombinants, used in the in vitro acetylation assay were enzymatically digested into peptides using enzyme Glu-C and the peptides were analyzed by micro-liquid chromatography-tandem mass spectrometry (LC-MS/MS). The peptides containing K29, K136, and K198 residues were identified as acetylated peptides, and the levels of acetylation were increased after the autoacetylation reaction (Supplementary Table S1 ). Extracted ion chromatograms of the peptides containing acetylated lysine from control and autoacetylated recombinant proteins were used to compare the level of acetylation (Supplementary Fig. S1 ). The identity of these peptides and the positions of the acetylation sites were manually validated using the fragment ions in the MS/MS spectra ( Fig. 2A) .
We produced a K29R/K136R/K198R triple mutant and performed an in vitro acetylation assay. WT hARD1 acetylated itself in a time-dependent manner, whereas K29R/K136R/ K198R triple mutant did not (Fig. 2B) . We then created K29R, K136R, and K198R single-point mutants and applied them in the acetylation assay. Acetylation of hARD1 mostly vanished in K136R single-point mutant and slightly decreased in K198R mutant (Fig. 2C ). In addition, as the effects of K136R single mutant and K136R/K198R double mutant were much the same, the amount of K198 acetylation might be negligible compared with that of K136 acetylation; therefore, we focused on K136 as a crucial site of autoacetylation (Fig. 2D, left) . As controls, K148R and K183R mutants, which are adjacent and far away from K136, respectively, did not have any effect on the autoacetylation of hARD1 (Fig. 2D,  right) . Therefore, these results clearly show that K136 is a critical autoacetylation site of hARD1.
Autoacetylation of hARD1 is reversibly regulated in vivo
We next examined whether hARD1 is also acetylated in vivo. GFP-hARD1 was recognized by the anti-acetyl-lysine antibody (Fig. 3A) ; moreover, acetylation of hARD1 was abrogated when K136 was substituted with R, indicating that acetylation also occurs at K136 residue in vivo (Fig. 3B) . Residual acetylation in K136R mutant might be due to minor autoacetylation of hARD1 occurring at K29 or K198 residue. Acetylation of R82A/Y122F mutant lacking catalytic activity was not detected at all by the anti-acetyl-lysine antibody, showing that acetylation of hARD1 is also mediated by itself in vivo (Fig. 3B) . In addition, although myc-tagged WT hARD1 binds to GFP-tagged R82A/Y122F mutant ( Supplementary  Fig. S2 ), R82A/Y122F mutant was not acetylated in vivo compatibly with in vitro (data of Fig. 1D ). Furthermore, when cells were placed in the treatment of sodium butyrate, histone deacetylase (HDAC) inhibitor, the acetylation level of endogenous hARD1 was increased in a dose-dependent manner (Fig. 3C ). In contrast with WT hARD1, the acetylation level of K136R and R82/Y122F mutants did not increase by sodium butyrate (Fig. 3D) . These results suggest that autoacetylation of hARD1 at K136 is reversibly regulated in vivo.
Autoacetylation of hARD1 upregulates cyclin D1 by β-catenin activation
Although the molecular mechanism of hARD1 remains mostly unclear, a recent study reported that hARD1 directly acetylates β-catenin, which is a transcription factor for cyclin D1 (12) . To address whether autoacetylation regulates the enzymatic activity of hARD1, acetylation of β-catenin was evaluated both in vitro and in vivo. Whereas GST-WT hARD1 directly acetylated GST-β-catenin in vitro, GST-K136R and GST-R82A/Y122F mutants failed to acetylate GST-β-catenin (Fig. 4A, left) . In HEK293T cells, acetylation of β-catenin was also reduced by K136R or R82A/Y122F mutant compared with that induced by WT hARD1 (Fig. 4A, right) , indicating that autoacetylation of hARD1 enhances its catalytic activity. Moreover, when HEK293T cells were treated with LiCl, which is known to activate β-catenin, WT hARD1 significantly increased the transcriptional activity of β-catenin/TCF4 reporter construct, whereas the K136R and R82A/Y122F mutant did not (Fig. 4B) . Furthermore, ChIP analysis showed that WT hARD1 augmented LiCl-induced recruitment of β-catenin on the cyclin D1 promoter, whereas K136R and R82A/Y122F mutants did not (Fig. 4C) . Consistent with these results, knockdown of hARD1 completely inhibited cyclin D1 expression (Fig. 4D, left) . WT hARD1 induced a slight increase in cyclin D1 at mRNA and protein levels, whereas K136R and R82A/Y122F mutants did not (Fig. 4D, middle) . However, enhanced cyclin D1 expression induced by WT hARD1 seemed to be minor because endogenous hARD1 might be already sufficient for cyclin D1 expression. To more clearly show the effect of hARD1 on cyclin D1, we therefore treated siRNA targeting the 5′-UTR of endogenous hARD1 and observed that the reduced cyclin D1 in response to 5′-UTR hARD1 siRNA was successfully rescued by WT hARD1 but not by K136R and R82A/Y122F mutants in HeLa cells (Fig. 4D,  right) . These results indicate that autoacetylation of hARD1 is important for β-catenin-mediated cyclin D1 expression.
Autoacetylation of hARD1 activates AP-1 pathway
Recently, β-catenin was reported to cooperate with c-Jun and c-Fos, main components of AP-1 proteins, for the transcriptional activation of cyclin D1 during tumorigenesis (29, 30) . Thus, we hypothesized that hARD1 might regulate not only β-catenin pathway but also AP-1 pathway to effectively promote cyclin D1 expression. In cyclin D1 promoter reporter system, knockdown of hARD1 extensively decreased the luciferase activity of cyclin D1 promoter (Fig. 5A, left) . Moreover, WT hARD1 effectively recovered the luciferase activity of cyclin D1 promoter reduced by knockdown of hARD1, whereas K136R and R82A/Y122F mutants did not (Fig. 5A, left) . Intriguingly, deletion of the AP-1 binding site (TRE) in cyclin D1 promoter dramatically diminished the ability of WT hARD1 to activate the cyclin D1 promoter, suggesting that hARD1 might regulate cyclin D1 expression through the AP-1 binding site. Reporter gene analysis using a multimerized consensus AP-1 binding site (5xTRE) promoter further verified this hypothesis. AP-1 activity was significantly decreased by knockdown of hARD1, and this reduced AP-1 activity was successfully rescued by WT hARD1 but not by Figure 2 . Autoacetylation of hARD1 mainly occurs at Lys 136 residue. A, identification of acetylated residues of hARD1. Acetylation sites were identified by LC-MS/MS. Identified acetylated residues are denoted as K*. B to D, autoacetylation site of hARD1. WT hARD1 and lysine site-mutated hARD1 were subjected to the in vitro acetylation assay, followed by Western blot analysis with the anti-acetyl-lysine antibody.
K136R and R82A/Y122F mutants (Fig. 5A, right) . To determine whether hARD1 induces AP-1 activation, we treated cells with TPA, a physiologic activator of AP-1 (31). Knockdown of hARD1 significantly decreased expression of c-Jun and c-Fos induced by TPA (Supplementary Fig. S3A ). Moreover, WT hARD1 enhanced TPA-induced expression of c-Jun and c-Fos, whereas K136R or R82A/Y122F mutant reduced the elevation in c-Jun and c-Fos expression (Fig. 5B) . The classic AP-1 target genes cyclooxygenase-2 (COX-2) and matrix metalloproteinase-1 (MMP-1) also showed similar expression patterns ( Supplementary Fig. S3B and C) .
We next evaluated whether hARD1 could regulate endogenous AP-1 DNA binding activity. Knockdown of hARD1 severely impaired the responsiveness of AP-1 to TPA (Supplementary Fig. S4A ). Moreover, WT hARD1 enhanced TPAinduced DNA binding activity of AP-1, whereas K136R or R82A/Y122F mutant did not (Fig. 5C) . Addition of c-Jun or c-Fos antibody to the binding reactions induced a supershift, confirming the presence of c-Jun and c-Fos proteins in the DNA-protein complexes. Furthermore, ChIP analysis also validated that knockdown of hARD1 inhibited the c-Jun and c-Fos recruitment on the cyclin D1 promoter ( Supplementary  Fig. S4B ). Accordingly, c-Jun and c-Fos were highly enriched on the cyclin D1 promoter of WT hARD1-overexpressing cells; however, these levels were reduced in K136R or R82A/Y122F mutant-expressing cells after TPA treatment (Fig. 5D ). Because AP-1 is regulated by the mitogen-activated protein kinase pathway (32-34), upstream signaling pathways were investigated. Phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) was significantly decreased by knockdown of ARD1 and increased by WT hARD1 ( Supplementary  Fig. S4C and D) . However, K136R and R82A/Y122F mutants did not significantly influence ERK1/2 activation ( Supplementary  Fig. S4D ). These results suggest that autoacetylation of hARD1 is required for AP-1 activation mediated by ERK1/2.
Autoacetylation of hARD1 promotes cell proliferation and tumorigenesis
Finally, we examined the biological roles of autoacetylation of hARD1 in cancer progression. When the WT or mutant hARD1 plasmids were introduced into A549, HeLa, and HEK293T cells, WT hARD1 enhanced cell growth, defining the overriding role of hARD1 autoacetylation as a stimulator of cancer cell proliferation, whereas K136R and R82A/Y122F mutants did not enhance cellular growth and even decreased it. In cyclin D1 silencing cells, the growth-promoting effect of WT hARD1 is severely abrogated compared with that in control siRNA-treated cells, confirming that cyclin D1 is indeed involved in growth-promoting effect of hARD1 autoacetylation (Fig. 6A) . The thymidine incorporation assay also revealed a similar phenomenon, showing increased cell proliferation by WT hARD1 but not by K136R and R82A/Y122F mutants (Fig. 6B) . In anchorage-independent colony formation assay, a significantly elevated colony number was observed in WT hARD1-expressing cells compared with that in K136R or R82A/Y122F mutant-expressing cells (Fig. 6C) .
Moreover, the effect of autoacetylation on tumor growth was investigated in a nude mouse xenograft model in which mice were injected s.c. with WT, K136R, or R82A/Y122F hARD1-expressing H460 human lung cancer cells. Remarkably, Figure 3 . Autoacetylation of hARD1 is reversibly regulated in vivo. A, hARD1 is acetylated in vivo. HeLa cells were transfected with GFP or GFP-hARD1 expression vector. Extracts were immunoprecipitated with anti-acetyl-lysine antibody and immunoblotted with an anti-GFP antibody. B, K136 residue of hARD1 is acetylated in vivo. myc-tagged hARD1 plasmids were transiently expressed in HeLa cells. Cell lysates were immunoprecipitated with an anti-myc or an anti-acetyl-lysine antibody and immunoblotted with anti-acetyl-lysine or anti-myc antibody, respectively. C, acetylation of endogenous hARD1 is reversibly regulated by HDAC inhibitor. HEK293T cells were exposed to 0, 1, and 5 mmol/L sodium butyrate (SB) for 4 h. Cell lysates were then immunoprecipitated with an immunoglobulin G (IgG) and an anti-acetyl-lysine antibody and immunoblotted with anti-hARD1 antibody. D, acetylation at K136R residue is enhanced by HDAC inhibitor. myc-tagged WT hARD1 or mutant hARD1 plasmid-transfected A549 cells were incubated with 5 mmol/L sodium butyrate for 4 h. Cell extracts were prepared and subjected to immunoprecipitation analysis with an anti-acetyl-lysine antibody.
primary tumor growth was significantly impaired in mice bearing K136R or Y82A/Y122F mutant-expressing cells compared with mice bearing WT hARD1-expressing cells (Fig. 6D) , confirming that hARD1 contributes to cell proliferation and tumorigenesis through its autoacetylation. Therefore, we proposed that autoacetylation of hARD1 is a key switch for modulating cancer cell proliferation and tumorigenesis.
Discussion
Several recent studies suggested that hARD1 is a potential drug target in cancer treatment and that it will be crucial to develop specific inhibitors of hARD1 (21, 35) ; however, the regulation of biological activity of hARD1 and its underlying molecular mechanisms are poorly understood. This is the first report to describe the autoregulatory mechanism Figure 4 . Autoacetylation of hARD1 regulates cyclin D1 expression through β-catenin activation. A, left, autoacetylation of hARD1 provokes acetylation of β-catenin in vitro. GST-hARD1 and GST-β-catenin recombinants were subjected to the in vitro acetylation assay for 2 h. Acetylated proteins were detected by anti-acetyl-lysine antibody. Coomassie brilliant blue staining shows the quantification of the input proteins. Right, autoacetylation of hARD1 enhances the acetylation level of β-catenin in vivo. myc-hARD1 and GFP-β-catenin plasmids were transfected in A549 cells. Cell extracts were prepared and subjected to immunoprecipitation analysis with an anti-acetyl-lysine antibody. B, autoacetylation of hARD1 enhances the transcriptional activity of β-catenin/TCF4. HEK293T cells were cotransfected with β-catenin/TCF4 luciferase plasmids and hARD1 plasmids and then treated for 16 h with 30 mmol/L LiCl. Luciferase activities were analyzed with a luminometer, and transfection efficiencies were normalized by β-Gal assays. *, P < 0.001; **, P < 0.005. C, autoacetylation of hARD1 promotes the binding of β-catenin/TCF4 to cyclin D1 promoter. ChIP was performed using anti-β-catenin antibody. Following DNA purification, the presence of selected DNA sequences was amplified by primers spanning cyclin D1 promoter. D, autoacetylation of hARD1 regulates cyclin D1 expression. A549 (left and middle) and HeLa (right) cells were transfected with hARD1 siRNA or indicated plasmids, and the expression level of cyclin D1 was analyzed by reverse transcription-PCR (RT-PCR) and Western blot analyses.
of hARD1, related with cell proliferation activity. Similar to other autoacetyltransferases, hARD1 undergoes autoacetylation to ensure its functional activation. Intriguingly, hARD1 has similar structure with other autoacetyltransferases (36) , especially GCN5 ( Supplementary Figs. S5 and S6 ), suggesting that hARD1 may be a new member of the GCN5/PCAF histone acetyltransferase family.
LC-MS/MS and site-directed mutagenesis indicated that autoacetylation of hARD1 mainly occurs at K136 residue. Although LC-MS/MS data revealed that hARD1 undergoes Figure 5 . Autoacetylation of hARD1 is required for AP-1 activation. A, left, hARD1 regulates cyclin D1 through AP-1 binding site. After transfection of hARD1 siRNA and hARD1 plasmids into HEK293T cell, reporter assays were performed using cyclin D1 promoter (−961 to +134) luciferase plasmids with or without AP-1 binding site (TRE). Luciferase activities were analyzed with a luminometer, and transfection efficiencies were normalized by β-Gal assays. *, P < 0.005. Right, autoacetylation of hARD1 is required for transcriptional activity of AP-1. The roles of WT and mutant hARD1 in activating AP-1 transcriptional activity were determined using a 5xTRE promoter luciferase plasmid in hARD1 silencing HEK293T cells, as described above. *, P < 0.005. B, autoacetylation of hARD1 enhances AP-1 expression. A549 cells were transfected with indicated plasmids, and the cells were treated with 100 nmol/L TPA for the indicated times. RT-PCR and Western blot analyses were performed to evaluate the expression levels of c-Jun and c-Fos. C, autoacetylation of hARD1 increases DNA binding activity of AP-1. Electrophoretic mobility shift assay was performed using oligonucleotides corresponding to the AP-1 consensus site with nuclear extracts from indicated plasmid-expressing HeLa cells. Supershift experiments were performed using anti-c-Jun and anti-c-Fos antibodies. Arrows and dotted red boxes indicate the supershifted band of the DNA-protein complex. D, autoacetylation of hARD1 augments the binding of AP-1 to cyclin D1 promoter. After indicated plasmid was introduced into A549 cells, cells were incubated with 100 nmol/L TPA. Subsequently, ChIP was performed using anti-c-Jun and anti-c-Fos antibodies. Following DNA purification, the presence of selected DNA sequences was assessed by PCR. autoacetylation in at least three lysine residues, including K29, K136, and K198, among them K136R substitution was the most efficient to abrogate the autoacetylation of hARD1; we therefore conclude that K136 is a crucial autoacetylation site of hARD1.
Our results are inconsistent with a previous report showing that recombinant hARD1 acetylates its NH 2 -terminal Gly residue but not any of internal lysine residues in vitro (37) . To further verify the internal lysine acetylation, the NH 2 -terminal region of hARD1 was cleaved with thrombin to remove labeled NH 2 -terminal Gly. The [ 14 C]acetyl group remained in the thrombin-cleaved hARD1 recombinant, confirming the internal lysine acetylation of hARD1 (Supplementary Fig. S7A ). One possible explanation for these conflicting results is the labile catalytic activity of recombinant hARD1. Consistent with the previous study characterizing the fibrillar conformation of recombinant hARD1 (38) , recombinant hARD1 formed aggregates over times; thus, only freshly prepared hARD1 could undergo autoacetylation (Supplementary Fig. S7B ).
Autoacetylation has been generally accepted to be required for the catalytic and biological activation of acetyltransferases. The significance of the autoacetylation of hARD1 was revealed by the observation that nonacetylated K136R or R82A/Y122F mutant-expressing cells showed limited proliferation rates (Fig. 6) . These results imply that nonacetylated mutant hARD1 might compete with endogenous hARD1. As K136R and R82A/Y122F mutants bind to WT hARD1 ( Supplementary Fig. S2 ), it is possible that these Figure 6 . Autoacetylation of hARD1 promotes cell growth and tumorigenesis. A, autoacetylation of hARD1 promotes cell proliferation. In A549, HeLa, and HEK293T cells, myc-hARD1 plasmids were introduced in control (white columns) or cyclin D1 (black columns) siRNA-transfected cells. After 3 d, the growth of A549, HeLa, and HEK293T cells was determined by MTS assay. *, P < 0.01; **, P < 0.005. B, autoacetylation of hARD1 increases thymidine incorporation into cells. HEK293T cells transfected with the indicated plasmids were incubated with 1 mCi/mL [ mutants function in a dominant-negative manner by forming heterodimer with endogenous hARD1.
Previously, Lim et al. (12) showed that hARD1 directly binds and activates β-catenin, which is a transcription factor for cyclin D1, and thereby upregulates cyclin D1 expression in human lung cancer cells. In our results, β-catenin activation on cyclin D1 promoter induced by WT hARD1 was abrogated by substitution with K136R or R82A/Y122F, suggesting that autoacetylation is required for the enzymatic activity of hARD1 (Fig. 4C) .
Recent studies have shown that β-catenin pathway cooperates with AP-1 components during tumorigenesis (30) . β-Catenin directly interacted with c-Jun and c-Fos, and this complex was involved in the transcriptional induction of cyclin D1; thus, synergistic mechanism between the β-catenin/ AP-1 signalings contributed to cancer development (29) . In our results, c-Jun and c-Fos were upregulated by WT hARD1, but not by K136R or R82A/Y122F hARD1, indicating that autoacetylation of hARD1 is also required for AP-1 pathway activation (Fig. 5) . Moreover, deletion of the AP-1 binding site (TRE) in the cyclin D1 promoter reduced the ability of hARD1 to activate the cyclin D1 promoter through β-catenin (Fig. 6A) . Therefore, there is a possibility that hARD1 could be an upstream molecule regulating the cooperation between the β-catenin/AP-1 signaling cascades in cancer progression.
Activation of AP-1 is a characteristic of many tumors (39) (40) (41) . In various human cancers, c-Jun and c-Fos are expressed at a high level and play a central role in tumor progression (42) (43) (44) . It was recently reported that hARD1 is also highly expressed in diverse human cancers (19) (20) (21) (22) , in which AP-1 is upregulated, consistent with our results showing that hARD1 increases AP-1 activation.
In conclusion, our results reveal a molecular mechanism whereby hARD1 contributes to tumorigenesis. Autoacetylation of hARD1 promotes cyclin D1 expression through activations of β-catenin and AP-1, which are crucial for tumor cell growth. Significantly, the blocking of hARD1 autoacetylation remarkably inhibited tumor growth in vivo (Fig. 6D) , suggesting that the regulation of the acetylated status of hARD1 will be applicable to cancer treatment. Our findings, therefore, offer an insight into the function of hARD1 in cancer development and can provide a clue to inhibit hARD1 activation for cancer treatment.
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